Literature DB >> 35292857

Links of platelet glutamate and glutathione metabolism with attenuated positive and negative symptoms in depressed patients at clinical high risk for psychosis.

Irina S Boksha1, Maria A Omel'chenko2, Olga K Savushkina3, Tatyana A Prokhorova3, Elena B Tereshkina3, Elena A Vorobyeva3, Gulnur Sh Burbaeva3.   

Abstract

Aim of the study is to reveal clinical and biological correlations in patients with adolescent depression and attenuated psychotic symptoms. Activity of platelet enzymes involved in glutamate-, glutathione- and energy metabolism was evaluated in control group and in the patients, because these systems are suspected as related to pathogenesis of psychosis. Adolescents (78 men, 16-25 years old) hospitalized with the first acute depressive state composed two groups: with prevalence of attenuated psychotic positive or negative symptoms (Gr1 and Gr2, 48 and 30 patients, respectively). Control group comprised 20 mentally healthy men of 19-25 years old. Gr1 differed significantly from Gr2 in scores by the Scale of Prodromal Symptoms (SOPS) for positive symptoms, p < 0.001, for disorganization symptoms, p < 0.003, and for total SOPS score, p < 0.001, before the treatment started. When patients from either Gr1 or Gr2 were compared with the control group, significantly decreased baseline activities of platelet glutamate dehydrogenase (GDH), glutathione reductase (GR) and glutathione S-transferase (GST) were found (p < 0.0001). Different correlations were found between baseline enzymatic activities in Gr1 and Gr2: GDH activity correlated with GR activity in Gr1 (R = 0.37), and with GST activity in Gr2 (R = 0.70). Significant correlations were found only in Gr2 between the delta of scores by SOPS negative symptoms (SOPS-N) under treatment and baseline GDH, GST, and GR activities (R = - 0.36, R = - 0.60, and R = 0.38, respectively). The found correlations of the baseline enzymatic activity levels with the value of the decrease (delta) in SOPS-N scores under the treatment represent interest for the prediction of the pharmacotherapy efficiency.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.

Entities:  

Keywords:  Adolescent-onset depression; Clinical high risk for psychosis; Glutamate dehydrogenase; Glutathione S-transferase; Glutathione reductase; Platelets

Year:  2022        PMID: 35292857     DOI: 10.1007/s00406-022-01396-7

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  38 in total

Review 1.  The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies.

Authors:  Wei Hu; Matthew L MacDonald; Daniel E Elswick; Robert A Sweet
Journal:  Ann N Y Acad Sci       Date:  2014-10-14       Impact factor: 5.691

Review 2.  A revised excitotoxic hypothesis of schizophrenia: therapeutic implications.

Authors:  S I Deutsch; R B Rosse; B L Schwartz; J Mastropaolo
Journal:  Clin Neuropharmacol       Date:  2001 Jan-Feb       Impact factor: 1.592

3.  The Latent Structure of Negative Symptoms in Individuals With Attenuated Psychosis Syndrome and Early Psychosis: Support for the 5 Consensus Domains.

Authors:  Wing Chung Chang; Gregory P Strauss; Anthony O Ahmed; Sandra C Y Wong; Joe K N Chan; Edwin H M Lee; Sherry K W Chan; Christy L M Hui; Sydney H James; Hannah C Chapman; Eric Y H Chen
Journal:  Schizophr Bull       Date:  2021-03-16       Impact factor: 9.306

Review 4.  Capturing the angel in "angel dust": twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans.

Authors:  Bita Moghaddam; John H Krystal
Journal:  Schizophr Bull       Date:  2012-08-16       Impact factor: 9.306

5.  Duration of attenuated positive and negative symptoms in individuals at clinical high risk: Associations with risk of conversion to psychosis and functional outcome.

Authors:  Ricardo E Carrión; Docia Demmin; Andrea M Auther; Danielle McLaughlin; Ruth Olsen; Todd Lencz; Christoph U Correll; Barbara A Cornblatt
Journal:  J Psychiatr Res       Date:  2016-06-26       Impact factor: 4.791

Review 6.  Neurobiology of schizophrenia spectrum disorders: the role of oxidative stress.

Authors:  Stephen J Wood; Murat Yücel; Christos Pantelis; Michael Berk
Journal:  Ann Acad Med Singapore       Date:  2009-05       Impact factor: 2.473

7.  From Onset and Prodromal Stage to a Life-Long Course of Schizophrenia and Its Symptom Dimensions: How Sex, Age, and Other Risk Factors Influence Incidence and Course of Illness.

Authors:  Heinz Häfner
Journal:  Psychiatry J       Date:  2019-04-16

Review 8.  Depression and Schizophrenia: Cause, Consequence, or Trans-diagnostic Issue?

Authors:  Rachel Upthegrove; Steven Marwaha; Max Birchwood
Journal:  Schizophr Bull       Date:  2017-03-01       Impact factor: 9.306

9.  Platelet glutamate dehydrogenase activity and efficacy of antipsychotic therapy in patients with schizophrenia.

Authors:  Olga K Savushkina; Elena B Tereshkina; Tatiana A Prokhorova; Irina S Boksha; Denis S Burminskii; Elena A Vorobyeva; Margarita A Morozova; Gulnur Sh Burbaeva
Journal:  J Med Biochem       Date:  2020-01-10       Impact factor: 3.402

10.  Interactions between hippocampal activity and striatal dopamine in people at clinical high risk for psychosis: relationship to adverse outcomes.

Authors:  Gemma Modinos; Anja Richter; Alice Egerton; Ilaria Bonoldi; Matilda Azis; Mathilde Antoniades; Matthijs Bossong; Nicolas Crossley; Jesus Perez; James M Stone; Mattia Veronese; Fernando Zelaya; Anthony A Grace; Oliver D Howes; Paul Allen; Philip McGuire
Journal:  Neuropsychopharmacology       Date:  2021-05-03       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.